Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (99)	8/9/1998 5:01:00 PM
From: EZLibra	Read Replies (1) \| Respond to of 666

Hi Rick, good to talk to you again. Some companies with 'strong currencies' have had an ongoing interest in TCLN technologies for years. They've just been waiting to acquire the assets at the sheriff's auction on the courthouse steps. Just ask the Coulter scientists, some of whom were part of the cause of the failure of the original Lym-1 trial when they worked at Lederle Labs (Lym-1 was successfully resurrected by the NCI and the Drs DeNardo at U.C.Davis). The difference now is that TCLN has graduated from merely being a survivor to a role as a serious contender not only in NHL but all cancers. The management of TCLN has promised a license for Oncolym soon but that is not what has us all so excited. As golfdad so eloquently explained it's TNT (tumor necrosis technology). It does look as if TNT is a pandemic cancer therapeutic. It's worthwhile to read almost any of Golfdad's posts on Yahoo (go to quote.yahoo.com enter TCLN, then enter golfdad 97 under search). He's amazing. Back to your questions though. Lon Stone is gone, doesn't even have an office now. Tom Testman is Chairman and Larry Bymaster is president and CEO, Lisa Frost is CFO. Updating of the web page should be completed in a week but their bio's are at techniclone.com Idec/Coulter by addressing and destroying the CD20 receptors, which are on all B-cells -healthy and cancerous - effectively compromises the immune system. No white blood cells means immunosuppression and the subject is open to any opportunistic infection such as tuberculosis. M. Winn has reported on this. Oncolym targets the HLA-dr receptor but only on cancerous B-cells. Consequently the immune system is left intact which in most intermediate grade and all high grade is very important since it can take nine months for the marrow to rebuild healthy B-cells. Many intermediate and hg NHL patients don't have an extra nine months. So what golfdad, M. Winn, and yourself seem to be endorsing is a cocktail which treats as many NHL receptors as possible, sort of like the triple HIV cocktails. These people are terminal, why not? I certainly agree. Where you hear disagreement is from diehard supporters of CLTR, IDPH and TCLN. I think Peter Ginsberg (Piper-Jaffray) is the only analyst who might say this publicly but this too will pass.

To: scaram(o)uche who wrote (99)	8/10/1998 10:01:00 AM
From: Vector1	Respond to of 666

Rick, I haven't followed TCLN for a long time. A long sordid history. CLTR is flush with cash and if there is a real threat they could step up. The party that should have the greater interest is GNE/IDPH. Bexxar is likely to take major market share away from Rituxin. I would also like to see data. Where is the evidence of adverse events from Bexxar or Rituxin related to destruction of the B cells. All of the approved products will be used in combination. In general Docs who specialize in low grade NHL are very aggresive about trying new formulations. Many will use Bexxar in combo with CHOP. V1